P3.03-052 Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma: Topic: Mesothelioma Clinical

Abstract

Malignant mesothelioma (MM) is an agressive tumor with poor prognosis, thus early assessment is important. We investigated the presence of mesothelin, osteopontin and megakaryocyte potentiation factor (MPF) levels in both sera and pleural effusions of MM patients and compared to the lung cancer, other malignancy, exudative and transudative effusions. Patients were enrolled into 5 study groups as demonstrated in table 1. Serum and pleural mesothelin, osteopontin and MPF levels of study groups were measured with enzyme-linked immunosorbent assay and compared with using convenient statistical methods. Mesothelin and osteopontin levels in both sera and pleural effusions were found to be statistically different among groups (Table 1). Pleural mesothelin and osteopontin levels were significant parameters to differentiate MM from the other groups (p=0.0001; p=0.002 respectively). When cut off value of pleural mesothelin level was set at 169.6ng/mL, sensitivity was 71.4 % and specificity was 88% for MM. When cut off value of pleural osteopontin level was set at 521.25ng/mL, sensitivity was 64.3% and specificity was 80% for MM (Figure 1). Pleural but not sera MPF level of MM patients was significantly higher than patients with lung cancer (p=0.021). Mesothelin, osteopontin and MPF levels can be used as diagnostic bio-markers to detect MM.